Drug Profile
SHR 0534
Alternative Names: SHR0534Latest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in China (PO)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in USA (PO)
- 01 Jan 2016 Jiangsu HengRui Medicine Co completes a phase I trial in Healthy volunteers in China (PO) (NCT02750553)